This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

The Health Kick Podcast with Tim Boreham

By Stockhead

Tim is Stockhead’s resident Health and Biotech expert with his weekly column “Dr Boreham’s Crucible”. Tim was the author of the Criterion column in The Australian newspaper for well over 10 years and has more than three decades’ experience of business reporting across three major publications. In his weekly “The Health Kick Podcast” Tim will interview Australia’s leading Health and Biotech industry leaders, bringing his own unique insight and perspective into the world of health and drug discovery.

  1. 1.
    The ASX's top performing 2019 IPO, Osteopore, discusses next steps, expansion plans and new markets11/10/2020
    23:49
  2. 2.
    Investors eye AdAlta's fibrosis fighting i-body platform11/10/2020
    22:43
  3. 3.
    Investors smell success in Rhinomed's flu and coronavirus nasal swab technology10/20/2020
    26:24
  4. 4.
    This biopharma company may be the world's only exosome-based player10/14/2020
    27:21
  5. 5.
    Investor confidence is sky-high in Apiam's diversified pet and livestock veterinarian offering09/18/2020
    23:48
  6. 6.
    PainChek's AI-backed pain assessment technology is a game-changer for treating infants and the elderly09/18/2020
    23:52
  7. 7.
    Investors still high on Incannex's cannabinoid pivot and COVID-19 treatment news09/15/2020
    25:10
  8. 8.
    Starpharma goes from strength to strength following news of progress on COVID-19 nasal spray08/31/2020
    19:00
  1. 9.
    Cannpal has first mover advantage in the $67bn "hidden gem" animal health market08/21/2020
    24:05
  2. 10.
    Chemo's diminishing role, the 'personalised' approach to cancer treatment and PTX's CAR-T innovations08/18/2020
    25:41
  3. 11.
    Zelira's cannabis-derived insomnia treatment has investors dreaming08/13/2020
    22:58
  4. 12.
    Botanix is using synthetic cannabinoids to treat acne and other skin conditions07/29/2020
    24:36
  5. 13.
    Pancreatic cancer treater OncoSil continues impressive bounce-back07/14/2020
    24:39
  6. 14.
    This drug developer is up 200 percent after being included in a COVID-19 related trial06/15/2020
    20:13
  7. 15.
    VTI has a clear vision for the future of contact lenses06/09/2020
    27:48
  8. 16.
    Cynata's stem cell therapy could be a game changer for COVID-19 patients06/03/2020
    21:53
  9. 17.
    Accurately measuring cognition offers massive upside to clinicians and drug makers, CGS is leading the charge05/18/2020
    27:21
  10. 18.
    Can Aussie drug makers survive COVID-19? And what can we learn from Chemgenex success?05/06/2020
    22:03
  11. 19.
    Chronic kidney disease is a worldwide health crisis, ASX-listed DXB driving improved treatment04/15/2020
    20:57
  12. 20.
    Increasing athletic performance and fighting sleep apnea with a simple nose clip03/31/2020
    24:13
  13. 21.
    Understanding immunotherapy, why the market dried up and Immutep's profitable potential03/17/2020
    20:46
  14. 22.
    Memphasys is using electrical forces on sperm to get better IVF results03/10/2020
    20:43
  15. 23.
    Understanding the strategy and upside behind global cannabis investment company MMJ03/05/2020
    20:11
  16. 24.
    Could oral sprays replace pills as a better means of drug delivery for some medicines?03/03/2020
    20:51
  17. 25.
    The ASX's only medicinal honey player, the market post bush fires and what Amazon offers producers02/26/2020
    22:37
  18. 26.
    Skyrocketing prescription drug prices, Trump's plan for the drug market and NOX's impressive pipeline02/19/2020
    23:17
  19. 27.
    Coronavirus, HIV and Hepatitis are in the sights of Aussie biotech Biotron02/12/2020
    24:07
  20. 28.
    Novel gene targeting therapies, protein disruptors and why ANP's recent trial success have investors buzzing02/05/2020
    25:03
  21. 29.
    Learning from the Swine flu pandemic, the market potential of exosome therapeutics and jumping ASX life-sciences hurdles01/29/2020
    20:52
  22. 30.
    Commercialising orphan drugs, the need for better biotech regulation the ASX's lifestyle play problems12/18/2019
    26:00
  23. 31.
    The science behind 2019's hottest IPO and the company's next steps12/11/2019
    21:07
  24. 32.
    Investing in repurposed drugs, combatting intracranial pressure and why Invex caught NASA's eye12/04/2019
    19:58
  25. 33.
    What's holding back better breast cancer detection? And how is Volpara's tech changing the game?11/27/2019
    21:45
  26. 34.
    Developing drugs, fighting fibrosis and squeezing squishometers11/20/2019
    23:44
  27. 35.
    How Aussie health stocks are performing internationally and Prescient's cancer-blocking innovation11/13/2019
    18:36
  28. 36.
    The growth of musculoskeletal disorders, new markets created by ageing populations and OCC's Avatar moment11/06/2019
    23:34
  29. 37.
    The future of X-ray, a new way to image the body and challenging clinical practice.10/29/2019
    20:47
  30. 38.
    The death of the doctor's clipboard, how Alcidion's infomatics saves lives and why it's best to bide time on a US entrance.10/24/2019
    21:59
  31. 39.
    Anatara Lifesciences: Standing out in the gut health market, solving scours in livestock and the future of antibiotics in the food chain.10/16/2019
    22:36
  32. 40.
    Kazia Therapeutics: Beating glioblastoma, crossing the blood-brain barrier and the joys of receiving a gong from Jacinda Ardern.10/09/2019
    20:40
  33. 41.
    BioScience Managers: Folding and holding in the biotech game, the perils of an early IPO and the slow burn of the Aussie health sector.09/30/2019
    26:47
  34. 42.
    Oventus Medical: The war on snoring, spousal homicide and the mouth guard that caught Alan Moss' eye.09/25/2019
    19:31

Listen to The Health Kick Podcast with Tim Boreham now.

Listen to The Health Kick Podcast with Tim Boreham in full in the Spotify app